Aptabio Therapeutics: Receives Phase 2 topline data for CIAKI drug Isuzinaxib (APX115)
AI reading
★★★★ Bullish · Material event
Phase 2 topline data received
An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).
For information only. Not investment advice.